Abstract
A prevalent eukaryotic N6-methyladensosine (m6A) post-transcriptional mark can be “erased” by the m6A demethylase FTO, which is commonly deregulated in acute myeloid leukemia (AML). In this issue of Cancer Cell, Huang et al. design small-molecule FTO inhibitors, FB23 and FB23-2, and demonstrate their potent inhibitory impact in AML models.
| Original language | English |
|---|---|
| Pages (from-to) | 540-541 |
| Number of pages | 2 |
| Journal | Cancer Cell |
| Volume | 35 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 15 Apr 2019 |
| Externally published | Yes |
Fingerprint
Dive into the research topics of 'The Yin and Yang of RNA Methylation: An Imbalance of Erasers Enhances Sensitivity to FTO Demethylase Small-Molecule Targeting in Leukemia Stem Cells'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver